ArticleBMJ open respiratory research2026
Sex differences in efficacy and adverse events following bronchoscopic thermal vapour ablation for severe emphysema: results from a multinational real-world registry.
Article in BMJ open respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research Progress and Comparative Evaluation of Three Cutting-Edge Chronic Obstructive Pulmonary Disease Treatment Strategies: Biologics, Bronchoscopic Lung Volume Reduction, and Stem Cell Therapies.International journal of chronic obstructive pulmonary disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBronchoscopic thermal vapour ablation (BTVA) is a treatment option for selected patients with severe emphysema, inducing lung volume reduction through a localised inflammatory response. This study investigated sex-specific differences in outcomes and safety after BTVA.
methodsData from the multicentre BTVA post-market registry (December 2018-July 2024) were retrospectively analysed. Sex-specific outcomes at 3, 6 and 12 months were compared, and the effect of sex on residual volume (RV%) was assessed using an adjusted mixed-effects model.
resultsA total of 231 patients (105 women) were included. In women, significant improvements were observed in forced expiratory volume in 1 s at 3, 6 and 12 months (+60 mL, +70 mL, +20 mL), RV at 6 and 12 months (-0.38 L and -0.50 L), 6-Minute Walk Distance (6-MWD) at 3 and 6 months (+17.5 m and +23.5 m), and a consistent improvement in St. George's Respiratory Questionnaire (SGRQ) at 3, 6 and 12 months (-9.3, -6.9, -9.1). In men, significant improvements were noted in RV at 3, 6 and 12 months (-0.32 L, -0.47 L, -0.32 L) and in SGRQ at 3 and 6 months (-4.8 and -3.7), but not at 12 months. An improvement in 6-MWD was not observed in men. Additionally, a significant time-by-sex interaction was observed for RV% (χ²=5.88, p=0.015), indicating distinct RV trajectories between the sexes.
conclusionsThe results indicate that women experienced greater improvements in lung function and SGRQ scores after BTVA, which may be explained by differences in perception and reporting of functional benefits, as well as potential biological factors such as a stronger inflammatory response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.